Resources

How comfortable are you in recommending the combination of a GLP-1 receptor agonist along with glargine insulin? 1- Very comfortable 2- Slightly comfortable 3- Neutral 4- Slightly uncomfortable 5- Very uncomfortable at this time Follow the link to share your response and see what your colleagues think!

Please select the drug class that best fits the description. This injectable drug class leads to increased insulin secretion, decreased glucagon secretion and slowed gastric emptying. One of its advantages is that its use can lead to weight loss: 1. DPP-4 inhibitors 2. GLP-1 receptor agonists 3. Dopamine-2 Agonists 4. SGLT-2 Inhibitors Did you get it right? Follow the link to find out!

Woman, 42 years of age. Type 1 diabetes for the past 22 years. I’ve been working with her and reviewing her CGM reports, and teaching about checking patterns before making changes in her pump settings.

Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 6 of this Exclusive Interview, Dr. Mechanick explains the changes to the AACE obesity treatment guidelines and how they impact current healthcare behavior.

In this week's conclusion of Homerun Slides: Continuous Glucose Monitoring in the Hospital, computerized glucose regulation in the ICU.

Physiologic effects of incretin hormones: GLP-1 -- The GLP-1 receptor has been detected on numerous organs and tissues. High levels of GLP-1 receptors have been found on pancreatic beta cells, delta cells, endothelial cells, cardiomyocytes, the gastrointestinal tract, and the kidneys.

Premarket Approval application submitted for Eversense® CGM system.

Sucralose may adversely affect glucose metabolism.

Two products approved by FDA will be available in 2017.

David Kliff, of the Diabetes Investor newsletter, attempts to explain why the cost of insulin is so high and how to solve the problem.